Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Sarcoma 1Dermatologic 1

Conditions

Melanoma 9Neoplasm Metastasis 3Urinary Bladder Neoplasms 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 6Paclitaxel 2Nivolumab 2Leucovorin 2Irinotecan 2Fluorouracil 2Drug Therapy 2Cyclophosphamide 2Carboplatin 2veliparib 1selinexor 1olaparib 1liposomal doxorubicin 1eribulin 1entinostat 1dehydroftorafur 1Topotecan 1Temozolomide 1Taxes 1Specimen Handling 1Ramucirumab 1Quality of Life 1Polymerase Chain Reaction 1Pemetrexed 1Patient Reported Outcome Measures 1Paracentesis 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1Microarray Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Decitabine × Dermatologic × Clear all
NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
15 enrolled 12 charts
DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡